The purpose of this study is to evaluate the safety and tolerability of single and multiple subcutaneous (SC) doses of MBX 4291 in adults with obesity.
Age of >18 to ≤65 years at the time of signing the informed consent.
Has a BMI of ≥30 to <50 kg/m2 at screening and baseline.
Weight-stable, i.e., no more than ±5% change in body weight for at least 3 months prior to screening and between screening and baseline.
History of, or currently active, significant illness or medical disorders that in the opinion of the investigator may preclude participants from participating in the study.
History of currently active pancreatitis, type I and type II diabetes.
Secondary causes of obesity, including but not limited to hypothalamic, monogenic, syndromic, or endocrine causes.
A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Parallel
MBX 4291
DrugMBX 4291 will be administered subcutaneously (SC)
Placebo
DrugPlacebo: Placebo will be administered subcutaneously (SC)
Number of participants with Treatment Emergent Adverse Events (TEAEs)
Click on the lead sponsor to view all of their trials.
